Background: A correct balance between protease and inhibitor activity is critical in the maintenance of homoeostasis; excessive activation of enzyme pathways is frequently associated with inflammatory disorders. Plasmin is an enzyme ubiquitously activated in inflammatory disorders, and Cl-inhibitor (Cl-Inh) is a pivotal inhibitor of protease activity, which is particularly important in the regulation of enzyme cascades generated in plasma. The nature of the interaction between plasmin and C l-Inh is poorly understood. Materials and Methods: Cl -Inh was immunoadsorbed from the plasma of normal individuals (n = 21), from that of patients with systemic lupus erythematosus (n = 18) or adult respiratory distress syndrome (n = 9), and from the plasma and synovial fluid of patients with rheumatoid arthritis (n = 18). As plasmin is a putative enzyme responsible for C l -Inh degradation, the interaction between plasmin and Cl -Inh was examined using SDS-PAGE. In addition, peptides cleaved from C l -Inh by plasmin were isolated and sequenced and the precise cleavage sites determined from the known primary sequence of Cl-Inh. Homology models of Cl-Inh were then constructed.
INTRODUCTION
Inflammation occurs as a result of the host's response to tissue injury and is a consequence of a complex series of interactions involving cellular and chemical mediators. The characteristic inflammatory bowel disease, rheumatoid arthritis (RA) and psoriasis and in other less common disorders such as systemic lupus erythematosus (SLE) and adult respiratory distress syndrome (ARDS) (1) . An important prerequisite for a successful inflammatory response and a return to homeostasis is the effective control of damaging enzymes generated during inflammation (1) . To this end, plasma protease inhibitors represent 10% of total plasma protein, controlling proteolytic events critical in the inflammatory response, such as those occuring during kinin, coagulation, fibrinolysis, and complement activation, as well as controlling the enzymes released from activated leucocytes (2, 3) . Serine protease inhibitors (serpins) are an important family of inhibitors that play an essential role in the regulation of serine proteases generated during inflammatory processes (4) . Their central role is underlined by deficiency states such as hereditary angioedema (CI-Inh deficiency) (5); emphysema (a-i-proteinase inhibitor deficiency) (6) ; recurrent hemorrage (a-2-anti-plasmin deficiency) (7); and thrombosis (antithrombin III deficiency) (8) . Furthermore, serpins behave as acute phase proteins and their synthesis is increased in response to tissue damage (9) .
Cl-inhibitor (CI-Inh) is a member of the serpin family that has a pivotal role in the control of proteases involved in the early phase of the inflammatory response. These proteases include proteins of the complement (CIr and C Is), kinin (plasma kallikrein), coagulation (factors Xla, Xlla and XIIf), and fibrinolytic (plasmin) pathways (5, 10) .
Deficiency of Cl-Inh leads to defective regulation of the inflammatory pathways and recurrent bouts of tissue swelling, or angioedema. These episodes of angioedema are thought to occur when C 1 -Inh is depleted to a critical level. Interestingly, Cl -Inh deficiency may be effectively treated with anti-plasmin agents, which suggests that plasmin activation is central to the pathogenesis of this disorder (10) . Plasmin, an enzyme activated during many inflammatory processes, is important in controlling fibrin deposition in tissue, which is a very early response to tissue injury (1 1). Furthermore, fibrin deposition and plasmin activation are hallmarks of many common inflammatory disorders. C 1 -Inh is thought to inhibit plasmin according to the general mechanism of serpin action; however, little is known about the Cl -Inh/plasmin interaction (2, 3, 10) . Early studies investigating the nature of the C l -Inh/plasmin encounter observed that it is different from the serpin mechanism of protease inhibition (12) (13) (14) .
In this study, we examined C l -Inh consumption and degradation in plasma from patients with a variety of inflammatory disorders as well as in plasma and synovial fluid from patients with active rheumatoid arthritis, and found increased levels of degraded, low molecular weight forms of C I -Inh. As plasmin is a putative enzyme involved in Cl -Inh degradation, the interaction between Cl -Inh and plasmin was examined in detail in vitro. Our results show that Cl -Inh is rapidly cleaved by plasmin at several sites in the molecule, resulting in inactivated Cl -Inh. Furthermore, degraded forms of C l -Inh, which were similar to those generated in vitro, were found in the plasma of patients with inflammatory disorders.
Local depletion of Cl-Inh by plasmin could contribute significantly to the pathogenesis of inflammatory conditions by altering the protease inhibitor balance. In addition, our results also provide an explanation for the efficacy of antiplasmin agents in the treatment of Cl-Inh deficiency states. Finally, it is also suggested that proteolytic degradation of other serpins could be an important pathogenic mechanism in other inflammatory processes.
MATERIALS AND METHODS
Examination of Cl-Inh Consumption and Degradation Blood from the following individuals was collected in siliconized vacutainer tubes to which EDTA (10 mM) and polybrene (0.05%, w/v) had been added to prevent in vitro activation of the complement and the contact system: 21 normal controls, 24 individuals with SLE, 18 patients with RA, and 9 patients with ARDS. Paired synovial fluids from the same RA patients were collected in an identical manner. Plasma and synovial fluid supernatant were obtained by centrifugation and were immediately aliquoted and stored at -700C. All processing was performed in plastic tubes. The plasma was thawed immediately before analysis. Cl-Inh was immunoadsorbed from plasma for analysis according to a previously published method (15) . The various forms of immunopurified C l -Inh were separated by SDS-PAGE (nonreduced) and visualized by Western blotting. Native, cleaved, and complexed forms of C 1 -Inh were scanned and quantified by densitometry.
SDS-PAGE SDS-PAGE (7.5% acrylamide) was performed according to the general method of Laemmli (16) Purification of Cl-Inhibitor C I -Inh was prepared from 200 ml of fresh frozen plasma using a modification of previously published procedures (17, 18 were incubated with nonreducing sample buffer and boiled for 4 min. These samples were analyzed by 7.5% SDS-PAGE and stained with CBB.
Purification of Plasminogen
Plasminogen was isolated from outdated plasma by lysine-Sepharose affinity chromatography and stored at -700C (19) . Just before use, plasminogen was activated by incubating it with streptokinase (Sigma) at 370C for 120 min, using a molar ratio of 200:1 plasminogen to streptokinase. The plasminogen was fully activated by streptokinase as visualized by 7.5% SDS-PAGE of reduced and nonreduced samples (results not shown).
Interaction of Cl-Inh with Plasmin and CIs in Vitro Equimolar quantities of Cl -Inh (0.16 mg/ml) were incubated separately with plasmin (0.35 387 mg/ml) or Cls (0.06 mg/ml) at 370C in PBS. At the end of 15-and 30-min incubation periods, identical aliquots of inhibitor and protease were incubated with nonreducing sample buffer, separated by 7.5% SDS-PAGE, and visualized with CBB.
Time Course of the Cl-Inh/Plasmin Interaction: SDS-PAGE Analysis Cl-Inh inactivates its target proteases through the formation of equimolar stoichiometric complexes between inhibitor and protease. Therefore, equimolar quantities of Cl-Inh (0.16 mg/ ml) and plasmin (0.35 mg/ml) were incubated under physiological conditions at 37°C in PBS. At varying time intervals (10 sec, 5, 15, 45, and 120 min), identical aliquots, calculated to contain approximately 10 ,ug of inhibitor and protease, were added to an equal volume of sample buffer and boiled for 4 min. The following controls were included: Cl-Inh in PBS, and plasmin in PBS. These samples were then subjected to 7.5% SDS-PAGE under nonreducing conditions and stained with CBB.
Isolation of Peptides Generated from Cl-Inh by Plasmin Using HPLC C1-Inh (0.16 mg/ml), plasmin (0.35 mg/ml), and Cl -Inh/plasmin (molar ratio 8:1 inhibitor to enzyme) were incubated in PBS, pH 7.2, at 370C for 60 min. At the end of this incubation period, each preparation was acidified with HCI to pH 4.5 to prevent further proteolysis.
The peptides generated from the C 1 -Inh/ plasmin interaction were purified on a Vydac C4 column (150 X 2 mm) equilibrated in 0.1% v/v trifluoroacetic acid, 2% v/v acetonitrile. Peptides were eluted with a linear gradient of 2 On the right, the 10 green spheres correspond to the proteolysis sites listed in Table 1 , as identified by residue labeling. On the left, three orange spheres indicate the a-carbon atoms of Glu 117, Cys 182, and Cys 406 which define the location of the major glycosylated N-terminal extension of Cl-Inh relative to the serpin fold (16 activity generated by the homeostatic pathways of coagulation, fibrinolysis, complement, and kinin pathways or by proteases released from tissues during inflammatory processes (4) . Activation of these pathways is a hallmark of many inflammatory disorders and contributes significantly to tissue damage in these situations. For example, the persistent inflammation and tissue damage observed in the joint in rheumatoid arthritis is partly mediated by the accumulation of the products of complement and coagulation activation (26) . For these reasons an important goal of the acute phase response is to limit proteolysis by increasing the availability of serpins (9) . Local serpin depletion could therefore have dramatic effects on the control of many physiological processes.
As Cl-Inh is a pivotal inhibitor controlling several inflammatory pathways, a polyclonal antibody capture assay was established to examine Cl-Inh consumption in vivo by measuring the relative amounts of native, cleaved, and complexed inhibitor circulating in plasma (15) . ClInh consumption was examined in the plasma from 21 normal individuals, 24 individuals with SLE, 9 individuals with ARDS, and the paired plasma and synovial fluid of 18 patients with RA. It was found that Cl -Inh circulates in three forms in normal plasma: native, cleaved, and complexed inhibitor migrating at 115, 96, and 209-225 kDa, respectively (Fig. 1) . However, Cl-Inh consumption and degradation was increased in all of the inflammatory disorders examined in comparison to normal plasma (Fig. 1) . This increase in Cl-Inh consumption was evident in the increased amount of cleaved and/or complexed inhibitor present. The pattern of cleavage found in patients with ARDS, for example, indicates considerable degradation of C I -Inh in vivo. This increased consumption of C I -Inh is probably a result of the increase in proteolytic activity associated with each of the inflammatory conditions. C l-Inh and plasmin were purified and incubated together and it is notable that the successful isolation of undegraded Cl -Inh requires the early removal of plasminogen (17, 18) . SDS-PAGE analysis of the C I -Inh/plasmin interaction revealed a decrease in the amount of 115-kDa Cl-Inh, new Cl-Inh derivatives at 96 and 83 kDa, and barely detectable amounts of high molecular mass complexes at 209 kDa and 198 kDa (Fig. 2) . Thus the main species generated when normal Cl -Inh interacts with plasmin migrated at 96 and 83 kDa. This is similar to the degraded forms of Cl-Inh circulating in the plasmas of patients with inflammatory disorders (Fig. 1) .
It has been previously shown that plasmin generates two derivatives of C 1 -Inh migrating at approximately 96 kDa, only one of which retained functional activity (12, 14) . The 83-kDa species has also been shown to be functionally inactive as it does not bind to activated Cl s (14) . Therefore, the major derivatives from the interaction between plasmin and Cl-Inh are inactivated Cl-Inh molecules. Further investigations of this interaction were aimed at identifying the precise cleavage events occurring. The strategy employed to identify cleavage sites was to isolate the peptides generated from C l-Inh by plasmin, perform amino acid sequence analysis of the isolated peptides, and in this way locate the precise cleavage sites on the Cl-Inh molecule. The peptides generated from Cl-Inh were successfully isolated by reverse phase chromatography (HPLC) (Fig. 4, Table 1 ). Plasmin cleaves Cl -Inh in a very specific manner at 1 arginine residue and 9 lysine residues (Fig. 5) . Even under limiting conditions, plasmin generates many peptides from Cl -Inh. All of the cleavage sites are at either lysine or arginine residues, although there is a strong preference for lysine. This is in keeping with the known amino acid target preference of plasmin. However, it is striking that the reactive site (Arg 444-Thr 445) (27, 28) located by other studies with Cl-Inh/Cls or Cl-Inh/plasma kallikrein, was not cleaved by plasmin under these conditions. This further reinforces the observations from the SDS-PAGE analysis (Fig. 4) that a minimal amount of plasmin is engaged and captured by Cl -Inh at its reactive site.
Spectroscopy indicates that large parts of the native serpin fold exist in a stressed state, and that cleavage of the reactive site loop relieves this general stress (29) . It is of interest that most plasmin cleavage sites occur close to the reactive site loop in the native protein (Fig. 6A) . Such cleavages would be expected to affect the integrity of the serpin fold by disruption of the 1B sheets B and C and the loops connecting these ( (Fig. 6B, yellow (Table 1) , the integrity of ,B sheets B and C will be disrupted (Fig. 6B, purple) , and this will have more severe effects on the physiological activity of Cl -Inh. This cleavage will ultimately lead to the generation of a C 1 -Inh cleavage product of 83 kDa.
The C 1 -Inh model also offers an explanation for the location of the plasmin cleavage sites. All the cleavage sites are distant from the heavily glycosylated N-terminal domain of Cl -Inh (Fig. 6A) . The position of the N-terminal domain is defined by covalent links to the serpin fold at His 141, Cysl82, and Cys4O6, and is positioned at the end of the serpin fold away from the plasmin cleavage sites (20) . The plasmin cleavage sites are distant from all three glycosylation sites at Asn216 and Asn231 at the end of the fold furthest from the reactive site, and also from Asn330 in the central region of the fold. The resulting steric hindrance offered by these four groups would direct plasmin activity toward the reactive site loop region at the other end of the serpin fold as depicted in Fig. 6 .
The results of the studies on patients' plasma show that degradation of Cl-Inh is a feature of several inflammatory situations. Although there are apparently large amounts of native Cl-Inh circulating in each of the disorders examined, local degradation of C I -Inh could lead to a loss of functional Cl -Inh activity at the site of inflammation. It is also confirmed that degradation of Cl -Inh can readily be accomplished in vitro by plasmin, an enzyme activated during many inflammatory disorders. In addition, the pattern of C 1 -Inh degradation in vivo is very similar to that occuring with plasmin in vitro. Furthermore, the isolation of uncleaved Cl-Inh (115 kDa) from plasma requires the early removal of plasmin, and the pattern of Cl-Inh cleavage (96 and 83 kDa) produced by plasmin has not been reported following incubation with other proteases. Although C I -Inh is not thought to be an important inhibitor of plasmin in vivo, it can readily be inactivated by plasmin.
Other studies have suggested that additional enzymes such as neutrophil elastase may also be responsible for the degradation of Cl-Inh (30) (31) (32) . These results raise intriguing possibilities with regard to the failure of the control of proteolysis occurring in inflammatory disorders. The results also suggest that specific treatment strategies aimed at either increasing serpin activity or diminishing protease action may offer an effective alternative therapeutic approach. In support of this, studies of endotoxin-induced ARDS have shown that C 1 -Inh infusion prevented the development of ARDS in animal models (33, 34) . Furthermore, purified preparations of protease inhibitors have proved to be effective therapy for some of the manifestations of fulminant sepsis in human trials (35) .
It has also been known for some time that the anti-plasmin agent epsilon-aminocaproic acid and its analogue tranexamic acid are effective in preventing attacks of edema in Cl-Inhdeficient patients (10) . Although these agents are potent inhibitors of plasmin and the fibrinolytic pathway, the precise mechanism by which they attenuate attacks of angioedema is unknown (10) . However, activation of the fibrinolytic, complement, and contact phase of blood coagulation has been documented during attacks of edema in Cl-Inh-deficient patients and it has been suggested that anti-plasmin agents exert their effect by directly inhibiting plasmin (36) (37) (38) . It has also been shown that a critical level of Cl -Inh is necessary to prevent attacks of angioedema (39) . As our results indicate that plasmin cleaves C 1 -Inh very effectively, it is probable that in situations of Cl -Inh deficiency, activation of plasmin may locally degrade C l-Inh and diminish the quantity of functional Cl -Inh available, thus predisposing to attacks edema. Therefore, anti-plasmin agents may be effective by blocking degradation of C I -Inh by plasmin.
In summary, it has been shown that high levels of inactivated C 1 -Inh, a pivotal inhibitor of the contact phase of inflammation, circulate in patients with a variety of inflammatory disorders. It has also been shown that plasmin rapidly degrades C 1 -Inh in vitro in a way very similar to that observed in inflammatory disease. We postulate that serpin degradation by proteases may be an important event furthering tissue damage in many common disorders. These findings provide an explanation for the efficacy of anti-plasmin agents in Cl -Inh deficiency disorders and they also have important implications for the design of therapeutic regimes in inflammatory diseases.
